Initial pulmonary respiration causes massive diaphragm damage and hyper-CKemia in duchenne muscular dystrophy dog

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Nakamura, Akinori ^a,b   Kobayashi, Masanori ^a,c   Kuraoka, Mutsuki ^a   Yuasa, Katsutoshi ^a   Yugeta, Naoko ^d   Okada, Takashi ^a   Takeda, Shin'Ichi ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

^d AZABU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; HYALIN; OSTEOPONTIN; TRANSCRIPTOME;

ANIMAL; ARTICLE; BLOOD; BREATHING; DIAPHRAGM; DISEASE MODEL; DOG; DUCHENNE MUSCULAR DYSTROPHY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; MOLECULAR GENETICS; NEWBORN; PATHOLOGY; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION;

ANIMALS; ANIMALS, NEWBORN; CREATINE KINASE; DIAPHRAGM; DISEASE MODELS, ANIMAL; DOGS; GENE EXPRESSION REGULATION; HYALIN; INFLAMMATION; MOLECULAR SEQUENCE ANNOTATION; MUSCULAR DYSTROPHY, DUCHENNE; OSTEOPONTIN; PROTEOLYSIS; RESPIRATION; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSCRIPTOME;

EID: 84880339278     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02183     Document Type: Article

References (45)

1. Sarkis, J. et al. Resisting sarcolemmal rupture: dystrophin repeats increase membrane-actin stiffness. FASEB 27, 359-369 (2012).
2. J?gensen, L.H. et al. Long-term blocking of calcium channels in mdxmice results in differential effects on heart and skeletal muscle. Am J Pathol 178, 273-83 (2011).
3. Tanabe, Y., Esaki, K. & Nomura, T. Skeletal muscle pathology in X-chromosomelinked muscular dystrophy (mdx) mouse. Acta Neuropathol (Berl.) 69, 91-95 (1986). (Pubitemid 16146255)
4. Valentine, B. A., Cooper, B. J., de lahunta, A., O'Quinn, R. & Blue, J. T. An animal model of Duchenne muscular dystrophy: clinical studies. J Neurol Sci 88, 69-81 (1988).
5. Shimatsu, Y. et al.Major clinical and histopathological characteristics of canine Xlinked muscular dystrophy in Japan, CXMDJ. Acta Myologica 24, 145-154 (2005). (Pubitemid 43287352)
6. Heyck, H., Laudahn, G. & Carsten, P. M. Enzymatktivita?sbestimmungen bei dystrophia musculorum progressia. IV. Mitterilung. Die serumenzymkinetik im pra?linischen stadium des typus Duchenne wa?rend der ersten 2 lebensjahre. Klin Wochnschr 44, 695-700 (1966).
7. Demos, J. Early diagnosis and treatment of rapidly developing Duchenne de Boulogne type myopathy (type DDBI). Am J Phys Med 50, 271-284 (1971).
8. Zellweger, H. & Antonik, A. Newborn screening for Duchenne muscular dystrophy. Pediatrics 55, 30-34 (1975).
9. Rudolph, N. & Gross, R. T. Creatine phsophokinase activity in serum of newborn infants as indicator of fetal trauma during birth. Pediatrics 38, 1039-1046 (1966).
10. Drumond, L. M. Creatine phosphokinase levels in the newborn and their use in screening for Duchenne muscular dystrophy. Arch Dis Child 54, 362-366 (1979).
11. Agnihotri, R. et al. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 276, 28261-28267 (2001).
12. Goncalves DaSilva, A., Liaw, L. & Yong, V. W. Cleavage of osteopontin by matrix metalloproteinase-12 modulates experimental autoimmune encephalomyelitis disease in C57BL/6 mice. Am J Pathol 177, 1448-1458 (2010).
13. Lanfossi,M. et al. Development ofmuscle pathology in canine X-linked muscular dystrophy. I. Delayed postnatal maturation of affected and normal muscle as revealed by myosin isoform analysis and utrophin expression. Acta Neuropathol 97, 127-138 (1999).
14. Malney, J. E., Alcom, D., Bowes, G. & Wilkinson, M. Development of the future respiratory system before birthe. Semin Perinatol 4, 251-260 (1980). (Pubitemid 11195496)
15. Scatena, M., Liaw, L. & Giachelli, C. M. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 27, 2302-2309 (2007). (Pubitemid 350203943)
16. Zanotti, S. et al.Osteopontin is highly expressed in severely dystrophicmuscle and seems to play a role in muscle regeneration and fibrosis. Histopathology 59, 1215-1228 (2011).
17. Pedersen, B. K.,A? kerstro?, T. C., Nielsen, A. R. & Fischer, C. P. Role ofmyokines in exercise and metabolism. J Appl Physiol 103, 1093-1098 (2007).
18. Mathers, J. A., Farnfield, M. M., Garnham, A. P., Caldow, M. K. & Cameron-Smith, D. Early inflammatory and myogenic responses to resistance exercise in the elderly. Muscle Nerve 46, 407-412 (2012)
19. Zheng, W. et al. Role of osteopontin in induction of monocyte chemoattractant proein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways inrheumatoid arthritis. Arthritis Rheum 60, 1957-1965 (2009)
20. Hirata, H. et al. Expression profiling of cytokines and related genes in regenerating skeletal muscle after cardiotoxin injection: a role for osteopontin.AmJ Pathol 163, 203-205 (2003).
21. Vetrone, S. A. et al.Osteopontin promotes fibrosis in dystrophic mousemuscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest 119, 1583-1594 (2009).
22. Dahiya, S. et al.Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne musucular dystrophy. J Immnol 187, 2723-2731 (2011).
23. Fukushima, K. et al.Activation and localization of matrix metalloproteinase-2 and-9 in the skeletal muscle of muscular dystrophy dog(CXMDJ).BMCMusculoskelet Disord 8, 54 (2007).
24. Dahiya, S. et al. Elevated levels of active matrix metalloproteinase-p cause hypertrophy in skeletal muscle of normal and dystrophin-deficient mdx mice. Hum Mol Genet 20, 4345-4359 (2011).
25. Qureshi, M. M. et al. The dietary supplement protandium decreases plasma osteopontin and improves markers of oxidative stress in muscular dystrophy mdx mice. J Diet Suppl 7, 159-178 (2010).
26. DaSilva, A. G., Liaw, L. & Yong, V. W. Cleavage of osteopontin by matrix metalloproteinase-12 modulates experimental autoimmune encephalomyeltitis disease in C57BL/6 mice. Am J Pathol 177, 1448-1458 (2010).
27. Wishart, M. J. & Dixon, J. E. PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease. TRENDS in Cell Biol 12, 579-585 (2002). (Pubitemid 35461856)
28. Kurek, J. B., Nouri, S., Kannourakis, G., Murphy, M. & Austin, L. Leukemia inhibitory factor and interleukin-6 are produced by diseased and regenerating skeletal muscle. Muscle Nerve 19, 1291-1301 (1996). (Pubitemid 26313826)
29. Schaefer, A.,Magocsi, M., Fandrich, A.& Marquardt, H. Stimulation of the Ca21-mediated egr-1 and c-fos expression in murine erythroleukaemia cells by cyclosporin A. Biochem J 355, 505-511 (1988).
30. Grembowicz, K. P., Sprague, D. & McNeil, P. L. Temporary disruption of the plasma membrane is required for c-fos expression in response to mechanical stress. Mol Biol Cell 10, 1247-1257 (1999). (Pubitemid 29193744)
31. Schuringa, J. J., Timmer, H., Luttickhuizen, D., Vellenga, E. & Kruijer, W. c-Jun and c-Fos cooperate with STAT3 in IL-6-induced transactivation of the IL-6 respone element (IRE). Cytokine 14, 78-87 (2001). (Pubitemid 32579260)
32. Cullen, E. M., Brazil, J. C. & O'Connor, C. M. Mature human neutrophils constitutively express the transcription factor EGR-1. Mol Immunol 47, 1701-1709 (2010).
33. Febbraio, M. A. & Pedersen, B. K. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 16, 1335-1347 (2002). (Pubitemid 34913306)
34. Peterson, J. M. & Pizza, F. X. Cytokines derived from cultured skeletal muscle cells after mechanical strain promote neutrophil chemotaxis in vitro. J Appl Physiol 106, 130-137 (2009).
35. McDonald, B. & Kubes, P. Cellular and molecular choreography of neutrophil recruitment to site of sterile inflammation. J Mol Med 89, 1079-1088 (2011).
36. Hodgetts, S., Radley, H., Davies, M. & Grounds, M. D. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice. Neuromuscl Disord 16, 591-602 (2006). (Pubitemid 44374323)
37. Gilroy, D. W. & Volville-Nash, P. R. New insights into the role of COX-2 in inflammation. J Mol Med 78, 121-129 (2000). (Pubitemid 30337493)
38. Messina, S. et al. Flavocoxid counteracts muscle necrosis and improves functional properties in mdxmice: a comparison study with methylprednisolone. Exp Neurol 220, 349-358 (2009).
39. Serra, F. et al. Inflammation in muscular dystrophy and the beneficial effects of non-steroidal anti-inflammatory drugs. Muscle Nerve 46, 773-784 (2012).
40. Uchino, M., Araki, S. & Miike, T. Correlative study of the incidence of opaque, necrotic and regenerative fibers in Duchenne dystrophy. Acta Neuropathol 75, 308-312 (1988). (Pubitemid 18051874)
41. Noguchi, S. et al. cDNA microarray analysis of individual Duchenne muscular dystrophy patients. Hum Mol Genet 12, 595-600 (2003). (Pubitemid 36372487)
42. Bushby, K. et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9, 77-93 (2010).
43. Frieri, M. Corticosteriod effects on cytokines and chemokines. Allergy Asthma Proc 20, 147-159 (1999).
44. Malcher-Lopes, R., Franco, A. & Tasker, J. G. Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic antiinflammatory switch. Eur J Pharm 583, 322-339 (2008).
45. Kobayashi, M. et al. Evaluation of dystrophic dog pathology by fat-suppressed T2-weighted imaging. Muscle Nerve 40, 815-826 (2009). Technology of Japan